Updates are available Correction dated 2024-04-10
Click to view Correction: https://doi.org/10.1007/s12325-024-02858-1
-
Authors
Lu, Mei
Rupp, Loralee B.
Melkonian, Christina
Trudeau, Sheri
Daida, Yihe G.
Schmidt, Mark A.
Gordon, Stuart C.
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 17 October 2023
Accepted: 21 November 2023
First Online: 2 January 2024
Change Date: 10 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-02858-1
Declarations
:
: Stuart C. Gordon receives grant/research support from AbbVie Pharmaceuticals, CymaBay, Genfit, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, and Viking Therapeutics. Mei Lu and Loralee B. Rupp receive research grant support from GlaxoSmithKline, AbbVie, and Intercept Pharmaceuticals. Yihe G. Daida receives research support from GlaxoSmithKline, Sanofi and Vir Biotech. Mark A. Schmidt receives research support from GlaxoSmithKline and Intercept Pharmaceuticals.
: The study follows all Declaration of Helsinki and US Department of Health and Human Services guidelines regarding the protection of human subjects. The CHeCS protocol was approved and is renewed annually by the institutional review boards (IRB) at each of the four sites (Henry Ford Health [HFH], Detroit, MI; Geisinger Health System [GHS], Danville, PA; Kaiser Permanente Northwest, Portland, OR; and Kaiser Permanente Hawaii, Honolulu, HI). The overarching CHeCS study protocol was approved by the HFH IRB (IORG0000148). Due to the de-identified nature of this observational study, requirements for written informed consent were waived.
